Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

Literature DB >> 1563386

Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

U Hjelm¹, J Kaustová, M Kubín, S E Hoffner.

Abstract

The susceptibility of Mycobacterium kansasii to antibacterial agents alone and in combination was studied. Widespread resistance to ethambutol, ciprofloxacin and isoniazid was found when these drugs were tested separately. However, pronounced antibacterial effects were seen when ethambutol was tested in combination with ciprofloxacin, rifampicin or rifabutin, which corresponded to significantly decreased resistance to these drugs in combination.

Entities: Chemical Species

Mesh：

Substances：

Year: 1992 PMID： 1563386 DOI： 10.1007/bf01971272

Source DB: PubMed Journal: Eur J Clin Microbiol Infect Dis ISSN： 0934-9723 Impact factor: 3.267

10 in total

1. Ethambutol: a key for Mycobacterium avium complex chemotherapy?

Authors: G Källenius; S B Svenson; S E Hoffner
Journal: Am Rev Respir Dis Date: 1989-07

2. Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.

Authors: S E Hoffner; S B Svenson; G Källenius
Journal: Eur J Clin Microbiol Date: 1987-10 Impact factor: 3.267

3. Basis for lack of drug susceptibility of atypical mycobacteria.

Authors: H L David
Journal: Rev Infect Dis Date: 1981 Sep-Oct

4. Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex.

Authors: S E Hoffner; G Källenius; A E Beezer; S B Svenson
Journal: Acta Leprol Date: 1989

5. Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media.

Authors: G Middlebrook; Z Reggiardo; W D Tigertt
Journal: Am Rev Respir Dis Date: 1977-06

6. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex.

Authors: S E Hoffner; M Kratz; B Olsson-Liljequist; S B Svenson; G Källenius
Journal: J Antimicrob Chemother Date: 1989-09 Impact factor: 5.790

7. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

Authors: N Rastogi; C Frehel; A Ryter; H Ohayon; M Lesourd; H L David
Journal: Antimicrob Agents Chemother Date: 1981-11 Impact factor: 5.191

8. Mycobacterium kansasii infection in an endemic area of Czechoslovakia.

Authors: M Kubín; E Svandová; B Medek; S Chobot; Z Olsovský
Journal: Tubercle Date: 1980-12

9. Determination of in vitro susceptibility of mycobacteria to ansamycin.

Authors: L B Heifets; M D Iseman
Journal: Am Rev Respir Dis Date: 1985-09

10. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods.

Authors: L B Heifets; M D Iseman; P J Lindholm-Levy; W Kanes
Journal: Antimicrob Agents Chemother Date: 1985-10 Impact factor: 5.191

10 in total

7 in total

Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

1. Ethambutol: a key for Mycobacterium avium complex chemotherapy?

2. Synergistic effects of antimycobacterial drug combinations on Mycobacterium avium complex determined radiometrically in liquid medium.

3. Basis for lack of drug susceptibility of atypical mycobacteria.

4. Studies on the mechanisms of the synergistic effects of ethambutol and other antibacterial drugs on Mycobacterium avium complex.

5. Automatable radiometric detection of growth of Mycobacterium tuberculosis in selective media.

6. In-vitro synergistic activity between ethambutol and fluorinated quinolones against Mycobacterium avium complex.

7. Multiple drug resistance in Mycobacterium avium: is the wall architecture responsible for exclusion of antimicrobial agents?

8. Mycobacterium kansasii infection in an endemic area of Czechoslovakia.

9. Determination of in vitro susceptibility of mycobacteria to ansamycin.

10. Determination of ansamycin MICs for Mycobacterium avium complex in liquid medium by radiometric and conventional methods.

1. Drug Susceptibility Profiling and Genetic Determinants of Drug Resistance in Mycobacterium kansasii.

Review 2. Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

Review 3. Pulmonary infections caused by less frequently encountered slow-growing environmental mycobacteria.

4. Susceptibility of Mycobacterium malmoense to antibacterial drugs and drug combinations.

Review 5. Clinical pharmacokinetics of rifabutin.

Review 6. Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy.

7. Therapy for Mycobacterium kansasii Infection: Beyond 2018.